Skip to Content

Express 5-HS

This page contains information on Express 5-HS for veterinary use.
The information provided typically includes the following:
  • Express 5-HS Indications
  • Warnings and cautions for Express 5-HS
  • Direction and dosage information for Express 5-HS

Express 5-HS

This treatment applies to the following species:
Company: Boehringer Ingelheim

Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine

Modified Live Virus

Haemophilus Somnus Bacterin

Express 5-HS Indications

For the vaccination of healthy, susceptible cattle as an aid in the reduction of respiratory diseases caused by Bovine Rhinotracheitis (IBR) virus, Bovine Virus Diarrhea (BVD) Types 1 and 2, Parainfluenza 3 (PI3) virus, and Bovine Respiratory Syncytial Virus (BRSV), and as an aid in the prevention of disease caused by Haemophilus somnus. This vaccine may be used in pregnant females or calves nursing pregnant females, provided the females were vaccinated pre-breeding according to label directions with any Express® FP vaccine.


The product in the amber glass vial contains IBR, Type 1 (Singer 1a cytopathic) and Type 2 (296 cytopathic), PI3, and BRSV modified live viruses. The plastic vial contains H. somnus in an adjuvant system. Contains neomycin as a preservative.

Directions and Dosage: Shake the accompanying bottle of bacterin diluent, then rehydrate the modified live virus vaccine by aseptically adding the diluent to the vaccine vial. Shake the rehydrated vaccine and use immediately. Using aseptic technique, inject 2 mL subcutaneously in front of the shoulder and midway of the neck, away from the suprascapular lymph node. If initial vaccination, repeat with BRSV and H. somnus vaccines in 14-28 days. Calves vaccinated before 6 months of age should be revaccinated at 6 months. A 2 mL booster dose is recommended annually. Pregnant cows and nursing calves may be vaccinated following a pre-breeding vaccination.

Summary Of Pregnant Cow Safety Study

Safety in pregnant cows and heifers was demonstrated in a field study that utilized more than 1600 cattle from three separate herds, as well as a serological study from a fourth herd. All cows and heifers enrolled in the study were vaccinated prior to breeding with Express® FP 10, a modified live virus (MLV) vaccine containing Infectious Bovine Rhinotracheitis (IBR), Bovine Virus Diarrhea (BVD) Type 1, BVD Type 2, Parainfluenza 3 (PI3), and Bovine Respiratory Syncytial Virus (BRSV), as well as Leptospira canicola, L. grippotyphosa, L. hardjo, L. icterohaemorrhagiae, L. pomona bacterin. Approximately one-third of the enrolled cattle were assigned to each one of the three trimesters. After confirmation of pregnancy status, a second vaccination was administered during the assigned trimester. Half of each trimester group was given Express® FP 10 and the remaining half was given the Lepto 5 bacterin. All of the enrolled cattle were observed closely through calving. Any fetal losses were recorded and fetuses were subjected to a full necropsy. Fetal losses were similar in both treatment groups. Overall fetal losses were 1.6% (13 of 810) in the test vaccination group and 1.9% (15 of 776) in the control group. There were no abortions or fetal losses diagnosed as due to IBR or BVD. The health of the calves from the enrolled cattle was monitored for 30 days after birth. There were no differences noted in the health status of calves between the two treatment groups.

In addition, a separate newborn calf serology study was conducted. A total of 120 calves from dams revaccinated in the second or third trimester were negative for pre-colostral antibodies to Bovine Virus Diarrhea Types 1 and 2 and Infectious Bovine Rhinotracheitis, further demonstrating that the Express® MLV products do not cause fetal infection when administered during pregnancy to previously vaccinated cows or heifers.

Fetal health risks associated with vaccination of pregnant animals with modified live vaccines cannot be unequivocally determined by clinical trials conducted for licensure. Management strategies based on vaccination of pregnant animals with modified live vaccines should be discussed with a veterinarian.

No vaccine can be expected to have 100% efficacy under all conditions. A small number of calves persistently infected with BVDV may have a devastating effect on herd health.


It is possible that healthy-appearing cattle can be persistently infected with or incubating virulent BVD virus at the time of vaccination. In view of these findings and suggested causes, BVD vaccine is contraindicated in persistently infected cattle and use should be limited only to healthy, immunocompetent, unstressed cattle.

Express 5-HS Caution

Animal inoculation only. Accidental injection into humans can cause serious local reactions. Contact a physician immediately if accidental injection occurs.


Store out of direct sunlight at 35-45°F (2-7°C). Avoid freezing. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Stressed cattle should not be vaccinated. Burn vaccine container and all unused contents. Injection site swelling may occur. Anaphylactoid reactions may occur. Antidote: Epinephrine.

Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO 64506

U.S. Veterinary License No. 124







10 Doses/Rehydrate with 20 mL

This package contains one 10 dose vial of MLV vaccine and one 20 mL vial of bacterin diluent.



50 Doses/Rehydrate with 100 mL

This package contains one 50 dose vial of MLV vaccine and one 100 mL vial of bacterin diluent.


CPN: 10280544

Telephone:   800-325-9167
Fax:   816-236-2717
Every effort has been made to ensure the accuracy of the Express 5-HS information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2020 Animalytix LLC. Updated: 2020-10-21